bisphosphonate bound paclitaxel / Atlanthera - LARVOL DELTA

Adjuvant Paclitaxel and Trastuzumab in Node-Negative, HER2-Positive Breast Cancer: Long-Term Follow-up (THE ASCO POST) - "In an analysis reported in The Lancet Oncology, Sara M. Tolaney, MD, MPH, and colleagues described 10-year survival outcomes from the phase II APT trial assessing adjuvant paclitaxel/trastuzumab in patients with node-negative, HER2-positive breast cancer...A total of 31 invasive disease-free survival events were observed: 6 (19.4%) were locoregional ipsilateral recurrences, 9 (29.0%) were new contralateral breast cancers, 6 (19.4%) were distant recurrences, and 10 (32.3%) were all-cause deaths."

Media quote

ACC 22: Results From the Chocolate-Touch Study (Radcliffe Group) - "In this late-breaking interview from ACC 2022, Dr Mehdi Shishehbor...discusses the outcomes of the Chocolate-Touch study, a multicentre prospective trial investigating the safety and effectiveness of the Chocolate Touch paclitaxel-coated balloon in superficial femoral or popliteal arteries compared to the commercially available Lutonix DCB (NCT02924857)."

Interview • Video

My Treatment Approach: Endometrial Carcinoma - Episode 7: Trastuzumab in Endometrial Carcinoma Therapy (OncLive) - "Bradley Monk, MD, FACOG, FACS: That's a good question. The patient was HER2 negative. David O'Malley, MD: As we look at this, without data, yes, I expect that arm is going to do better. I just haven't taken that leap. I am not advocating using I/O [immuno-oncology] therapy without first utilizing the carboplatin and paclitaxel. In my mind, this patient had already progressed on carboplatin, paclitaxel. I think it's really important to say, without data, the first-line therapy in metastatic recurrent endometrial carcinoma is still carboplatin, paclitaxel....It was not placebo controlled, but now that the survival advantage has been published by Amanda Nickles Fader, MD, in Clinical Cancer Research about 2 years ago, those patients with any advanced disease, including regional lymph node, benefited, particularly in the first-line setting. It's really important to keep that in mind regarding serous cancer of the uterus."

Video

Patient-Reported Outcomes Provide Additional Support for Pembrolizumab Combo in First-Line Cervical Cancer (Cancer Network) - "'Overall findings from KEYNOTE-826 support pembrolizumab plus chemotherapy with or without bevacizumab as the new standard of care for women with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 [combined positive score] of 1 or more,' Bradley Monk, MD...Eligible patients were randomized 1:1 to receive 200 mg of intravenous pembrolizumab or placebo every 3 weeks for 35 cycles plus intravenous paclitaxel, cisplatin, or carboplatin for up to 6 cycles with or without 15 mg/kg of intravenous bevacizumab every 3 weeks."

Media quote

Focusing on ADCs, Immodulators in Cervical and Endometrial Cancers (Targeted Oncology) - "The presentations are stratified by disease setting...during an interview with Targeted Therapies in Oncology. Presentations that focus on cervical cancer will kick off the meeting, with cochair Bradley J. Monk, MD...addressing the role of biomarkers for immunotherapy in cervical cancer."

Interview

New Research Seeks to Incorporate Immunotherapy into Early Lines of ESCC Treatment (Oncology Nursing News) - "'[Esophageal cancer] is a disease that is significant worldwide in terms of incidence and mortality, [as] the incidence ranks as No. 8 [and] the mortality is No. 6,' Nabil F. Saba, MD, said in an interview...'The majority of these patients have squamous cell cancer of the esophagus, [and] there has been little progress in advancing care for these patients over the last several decades, until very recently with the introduction of immunotherapy.'"

Interview

Potentially Game-Changing Clinical Trials in Endometrial Cancer Seek to Evaluate Immunotherapeutic Approaches (Oncology Nursing News) - "Many researchers are assessing the use of novel immunotherapies against chemotherapy to determine the ideal treatment strategy for frontline endometrial cancer, according to Bradley R. Corr, MD. 'Some of the most exciting trials that are coming out are going to look [at how to best leverage immunotherapy agents as] up-front therapy,' Corr said. 'One of the questions that [we hope to] answer in the not-too-distant future is: Is immunotherapy better, equivalent, or worse than chemotherapy? Combination therapy or single-agent [treatment] with immunotherapy could end up replacing chemotherapy.'"

Interview